[go: up one dir, main page]

AU2001292790A1 - Antisense modulation of syntaxin 4 interacting protein expression - Google Patents

Antisense modulation of syntaxin 4 interacting protein expression

Info

Publication number
AU2001292790A1
AU2001292790A1 AU2001292790A AU9279001A AU2001292790A1 AU 2001292790 A1 AU2001292790 A1 AU 2001292790A1 AU 2001292790 A AU2001292790 A AU 2001292790A AU 9279001 A AU9279001 A AU 9279001A AU 2001292790 A1 AU2001292790 A1 AU 2001292790A1
Authority
AU
Australia
Prior art keywords
syntaxin
protein expression
interacting protein
antisense modulation
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292790A
Inventor
Susan M Freier
Brett P Monia
Jacqueline R Wyatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2001292790A1 publication Critical patent/AU2001292790A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001292790A 2000-09-22 2001-09-19 Antisense modulation of syntaxin 4 interacting protein expression Abandoned AU2001292790A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09668313 2000-09-22
US09/668,313 US6503756B1 (en) 2000-09-22 2000-09-22 Antisense modulation of syntaxin 4 interacting protein expression
PCT/US2001/029251 WO2002024864A2 (en) 2000-09-22 2001-09-19 Antisense modulation of syntaxin 4 interacting protein expression

Publications (1)

Publication Number Publication Date
AU2001292790A1 true AU2001292790A1 (en) 2002-04-02

Family

ID=24681841

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292790A Abandoned AU2001292790A1 (en) 2000-09-22 2001-09-19 Antisense modulation of syntaxin 4 interacting protein expression

Country Status (4)

Country Link
US (1) US6503756B1 (en)
EP (1) EP1327002A2 (en)
AU (1) AU2001292790A1 (en)
WO (1) WO2002024864A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217807B2 (en) * 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US7427605B2 (en) * 2005-03-31 2008-09-23 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
KR20160036065A (en) * 2013-08-16 2016-04-01 라나 테라퓨틱스, 인크. Compositions and methods for modulating rna
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
AU2016344384A1 (en) 2015-10-26 2018-05-17 Translate Bio Ma, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
WO2021113541A1 (en) * 2019-12-06 2021-06-10 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256545A (en) * 1987-03-30 1993-10-26 Board Of Regents, The University Of Texas System Sterol Regulatory Elements
US5861244A (en) * 1992-10-29 1999-01-19 Profile Diagnostic Sciences, Inc. Genetic sequence assay using DNA triple strand formation
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
JPH10500281A (en) * 1994-02-14 1998-01-13 ザ マクファーレーン バーネット センター フォー メディカル リサーチ リミテッド Nonpathogenic HIV-1 species
US5814517A (en) * 1994-04-14 1998-09-29 Ligand Pharmaceuticals, Inc. DNA spacer regulatory elements responsive to cytokines and methods for their use
AU6657996A (en) * 1995-07-18 1997-02-18 Guido Krupp Ribozymes for the selective inhibition of expression by mhc llele genes, and drugs containing such ribozymes
NZ507640A (en) 1998-04-20 2003-12-19 Warner Lambert Co Gene encoding syntaxin interacting protein
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues

Also Published As

Publication number Publication date
US6503756B1 (en) 2003-01-07
WO2002024864A3 (en) 2002-05-30
EP1327002A2 (en) 2003-07-16
WO2002024864A2 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU6508499A (en) Antisense modulation of microtubule-associated protein 4 expression
AU2002227435A1 (en) Antisense modulation of calreticulin expression
AU2001229363A1 (en) Antisense modulation of caspase 3 expression
AU5239399A (en) Antisense modulation of g-alpha-13 expression
AU5587499A (en) Antisense modulation of g-alpha-16 expression
AU2001229447A1 (en) Antisense modulation of smad7 expression
AU4325199A (en) Antisense modulation of g-alpha-11 expression
AU5444300A (en) Antisense modulation of b7 protein expression
AU2001263171A1 (en) Antisense modulation of tert expression
AU1221201A (en) Antisense modulation of y-box binding protein 1 expression
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU5222899A (en) Antisense modulation of inhibitor-kappa b kinase-alpha expression
AU5321199A (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU2002228805A1 (en) Antisense modulation of damage-specific dna binding protein 2, p48 expression
AU2002226064A1 (en) Antisense modulation of talin expression
AU2001227848A1 (en) Antisense modulation of caspase 8 expression
AU2001287136A1 (en) Antisense modulation of glioma-associated oncogene-1 expression
AU2001292790A1 (en) Antisense modulation of syntaxin 4 interacting protein expression
AU5032501A (en) Use of cationic protein hydrolysates
AU6045499A (en) Antisense modulation of crel expression
AU2001289068A1 (en) Antisense modulation of caspase 2 expression
AU2379800A (en) Antisense modulation of fadd expression
AU5874800A (en) Antisense modulation of ets-2 expression
AU2001288907A1 (en) Antisense modulation of a20 expression